Ketone Bodies Improve Human CD8+ Cytotoxic T-Cell Immune Response During COVID-19 Infection

Severe COVID-19 is characterized by profound CD8 + T-cell dysfunction, which cannot be specifically treated to date. We here investigate whether metabolic CD8 + T-cell reprogramming by ketone bodies could be a promising strategy to overcome the immunoparalysis in COVID-19 patients. This approach was...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in medicine 2022-06, Vol.9, p.923502-923502
Hauptverfasser: Hirschberger, Simon, Gellert, Luca, Effinger, David, Muenchhoff, Maximilian, Herrmann, Markus, Briegel, Josef-Maria, Zwißler, Bernhard, Kreth, Simone
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Severe COVID-19 is characterized by profound CD8 + T-cell dysfunction, which cannot be specifically treated to date. We here investigate whether metabolic CD8 + T-cell reprogramming by ketone bodies could be a promising strategy to overcome the immunoparalysis in COVID-19 patients. This approach was triggered by our recent pioneering study, which has provided evidence that CD8 + T-cell capacity in healthy subjects could be significantly empowered by a Ketogenic Diet. These improvements were achieved by immunometabolic rewiring toward oxidative phosphorylation. We here report similar strengthening of CD8 + T cells obtained from severely diseased COVID-19 patients: Flow cytometry and ELISA revealed elevated cytokine expression and secretion (up to + 24%) upon ketone treatment and enhanced cell lysis capacity (+ 21%). Metabolic analyses using Seahorse technology revealed upregulated mitochondrial respiratory chain activity (+ 25%), enabling both superior energy supply (+ 44%) and higher mitochondrial reactive oxygen species signaling. These beneficial effects of ketones might represent evolutionary conserved mechanisms to strengthen human immunity. Our findings pave the road for metabolic treatment studies in COVID-19.
ISSN:2296-858X
2296-858X
DOI:10.3389/fmed.2022.923502